Browse News
Filter News
Found 1,269 articles
-
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
4/11/2024
The Executive Officers of Zai Lab Limited, Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of equity awards.
-
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
4/10/2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24 , at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.
-
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
4/2/2024
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2024
4/2/2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.
-
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or...
4/1/2024
Zai Lab Limited partner Bristol Myers Squibb announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C mutation, met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate as assessed by Blinded Independent Central Review at final analysis for these endpoints.
-
Gastroenterology Group of Naples Introduces Innovative Axonics Sacral Neuromodulation Therapy
3/19/2024
Gastroenterology Group of Naples, a partner practice of United Digestive, is pleased to announce the introduction of Axonics Sacral Neuromodulation Therapy to its list of advanced treatment options for those suffering from fecal incontinence.
-
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
3/18/2024
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
-
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
3/13/2024
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program.
-
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
3/12/2024
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024.
-
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
3/7/2024
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer.
-
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
3/6/2024
Zai Lab Limited announced that the final overall survival data from the Phase 3 randomized, double-blind, placebo-controlled NORA study evaluating ZEJULA® in Chinese patients with platinum-sensitive recurrent ovarian cancer will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology and the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer.
-
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink - March 1, 2024
3/1/2024
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer") to acquire all of the outstanding common shares.
-
BioMarin Scheduled to Participate in March Investor Conferences
3/1/2024
BioMarin Pharmaceutical Inc. today announced management is scheduled to participate in four upcoming investor conferences in March.
-
Thermo Fisher Scientific to Present at TD Cowen 44th Annual Health Care Conference on March 6, 2024
2/28/2024
Thermo Fisher Scientific to Present at TD Cowen 44th Annual Health Care Conference on March 6, 2024.
-
Congela Biocosmetics Announces Purchase of JuveXO to Propel the Use of Exosomes in Aesthetic Medicine
2/22/2024
Congela Biocosmetics, LLC. announced the acquisition of the JuveXO® brand and product line.
-
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
2/22/2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2023.
-
Thermo Fisher Scientific Increases Quarterly Dividend - February 21, 2024
2/21/2024
Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on April 15, 2024, to shareholders of record as of March 15, 2024.
-
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
2/8/2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m. ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update.
-
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
2/6/2024
BioMarin Pharmaceutical Inc. today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.
-
5 Companies Hiring Graduate Interns
2/1/2024
Here are the top companies on BioSpace with internship opportunities for graduate students.